# Fabrice Barlési

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/fabrice-barlesi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 73,321 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 100 |
| i10-index | 427 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5087836238 |
| ORCID iD | https://orcid.org/0000-0001-5793-3539 |
| Works | 1,476 |

## Researcher papers

Showing 12 of 32.

- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for/)
- [Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation](https://scholariq.org/papers/sotorasib-for-lung-cancers-with-i-kras-i-p-g12c-mutation/)
- [KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors](https://scholariq.org/papers/kras-sup-g12c-sup-inhibition-with-sotorasib-in-advanced-solid-tumors/)
- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group](https://scholariq.org/papers/recommendations-for-the-use-of-next-generation-sequencing-ngs-for-patients-with/)
- [Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)](https://scholariq.org/papers/routine-molecular-profiling-of-patients-with-advanced-non-small-cell-lung-cancer/)
- [Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-and-chemotherapy-in-non-small-cell-lung-cancer/)
- [Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-treated-brafv600e-mutant/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.